Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by STALICLA

Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs
From STALICLA
Via GlobeNewswire
Dr. Paulo Fontoura, MD, PhD, joins STALICLA as Chief Scientific and Clinical Development Advisor
From STALICLA
Via GlobeNewswire
STALICLA appoints Dr. Purnanand Sarma, PhD, as Chair of the Board of Directors
From STALICLA
Via GlobeNewswire
STALICLA publishes pioneering phase 1b data on precision treatment for autism spectrum disorder in Biomedicines
From STALICLA
Via GlobeNewswire
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder
From STALICLA
Via GlobeNewswire
Stalicla Secures $17.4 Million in Series B Financing to Propel Precision Neuro Advancements
From STALICLA
Via GlobeNewswire
STALICLA and Firefly Neuroscience enter Partnership Agreement for the Development of Electroencephalogram (EEG) as a Biomarker for Subgroups of Patients with ASD
From STALICLA
Via GlobeNewswire
STALICLA signs Cooperative Research and Development Agreement (CRADA) with US National Institute on Drug Abuse (NIDA) to cover Phase 3 development of mavoglurant in cocaine use disorder
From STALICLA
Via GlobeNewswire
STALICLA signs exclusive in-licensing agreement for late-stage clinical neuropsychiatric and neurodevelopmental disorder treatment
From STALICLA
Via GlobeNewswire
STALICLA Awarded EUR 1.7 Million to Lead Computational Drug Repositioning Activities in EU-funded REPO4EU Project
From STALICLA
Via Business Wire
STALICLA Completes Successful Phase 1b Trials for the First Precision Medicine in Autism Spectrum Disorder
From STALICLA
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.